Ultragenyx Pharmaceutical Inc (RARE) to Post FY2018 Earnings of ($3.98) Per Share, Jefferies Financial Group Forecasts

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) – Analysts at Jefferies Financial Group upped their FY2018 earnings per share (EPS) estimates for shares of Ultragenyx Pharmaceutical in a research note issued on Tuesday, November 6th. Jefferies Financial Group analyst M. Raycroft now expects that the biopharmaceutical company will post earnings of ($3.98) per share for the year, up from their prior forecast of ($4.27). Jefferies Financial Group also issued estimates for Ultragenyx Pharmaceutical’s Q4 2018 earnings at ($1.76) EPS, FY2019 earnings at ($5.73) EPS, FY2020 earnings at ($3.88) EPS and FY2021 earnings at ($1.31) EPS.

A number of other analysts have also weighed in on the company. Citigroup raised Ultragenyx Pharmaceutical from a “sell” rating to a “neutral” rating and increased their price objective for the company from $46.00 to $54.00 in a research note on Thursday. They noted that the move was a valuation call. Canaccord Genuity dropped their price objective on Ultragenyx Pharmaceutical from $90.00 to $75.00 and set a “buy” rating for the company in a research note on Wednesday. Raymond James raised their price target on Ultragenyx Pharmaceutical from $53.00 to $57.00 and gave the stock a “buy” rating in a research note on Tuesday. ValuEngine lowered Ultragenyx Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Monday, October 29th. Finally, Wedbush dropped their price target on Ultragenyx Pharmaceutical from $90.00 to $88.00 and set an “outperform” rating for the company in a research note on Monday, October 29th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and fifteen have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $75.95.

NASDAQ:RARE opened at $52.24 on Friday. The company has a market cap of $2.73 billion, a PE ratio of -6.97 and a beta of 2.34. Ultragenyx Pharmaceutical has a fifty-two week low of $41.67 and a fifty-two week high of $90.98.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Monday, November 5th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.94) by $0.20. The firm had revenue of $11.80 million during the quarter, compared to analyst estimates of $11.97 million. Ultragenyx Pharmaceutical had a negative return on equity of 41.08% and a negative net margin of 508.70%. The business’s quarterly revenue was up 5800.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.87) earnings per share.

In other Ultragenyx Pharmaceutical news, CFO Shalini Sharp sold 6,700 shares of the firm’s stock in a transaction on Tuesday, September 25th. The stock was sold at an average price of $90.07, for a total transaction of $603,469.00. Following the completion of the transaction, the chief financial officer now owns 56,828 shares of the company’s stock, valued at $5,118,497.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Karah Herdman Parschauer sold 5,000 shares of the firm’s stock in a transaction on Tuesday, August 21st. The shares were sold at an average price of $78.53, for a total value of $392,650.00. The disclosure for this sale can be found here. Insiders sold 37,250 shares of company stock valued at $2,747,319 in the last ninety days. 8.40% of the stock is currently owned by insiders.

A number of institutional investors have recently made changes to their positions in the business. Xact Kapitalforvaltning AB lifted its position in Ultragenyx Pharmaceutical by 10.6% during the second quarter. Xact Kapitalforvaltning AB now owns 7,323 shares of the biopharmaceutical company’s stock valued at $563,000 after buying an additional 700 shares during the period. GAM Holding AG lifted its position in Ultragenyx Pharmaceutical by 2.0% during the second quarter. GAM Holding AG now owns 50,700 shares of the biopharmaceutical company’s stock valued at $3,897,000 after buying an additional 1,000 shares during the period. Metropolitan Life Insurance Co. NY lifted its position in Ultragenyx Pharmaceutical by 7.3% during the second quarter. Metropolitan Life Insurance Co. NY now owns 15,187 shares of the biopharmaceutical company’s stock valued at $1,167,000 after buying an additional 1,037 shares during the period. State Board of Administration of Florida Retirement System lifted its position in Ultragenyx Pharmaceutical by 4.4% during the second quarter. State Board of Administration of Florida Retirement System now owns 26,319 shares of the biopharmaceutical company’s stock valued at $2,023,000 after buying an additional 1,100 shares during the period. Finally, Wells Fargo & Company MN lifted its position in Ultragenyx Pharmaceutical by 5.0% during the first quarter. Wells Fargo & Company MN now owns 24,200 shares of the biopharmaceutical company’s stock valued at $1,234,000 after buying an additional 1,149 shares during the period. 96.78% of the stock is owned by institutional investors and hedge funds.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.

See Also: Diversification Important in Investing

Earnings History and Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply